TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19573229

Group type: EXPERIMENTAL
Intervention: Participatory return-to-work (RTW) program developed using the Intervention Mapping (IM) protocol.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Identifying obstacles for RTW and formulating solutions for suitable (therapeutic) work with the help of an independent RTW coordinator.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assignment of a vocational rehabilitation agency to find a matching (therapeutic) workplace based on the RTW implementation plan.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of the participatory RTW program will be evaluated in a randomised controlled trial.
Number of subjects: 0
Study: 16919054

Group type: EXPERIMENTAL
Intervention: Quantitative sensory testing (QST) on the right and left cheeks and back of the hands
Number of subjects: 26

Group type: COMPARATOR
Intervention: Healthy subjects performing QST
Number of subjects: 26
Study: 15646911

Group type: EXPERIMENTAL
Intervention: EMLA (eutectic mixture of local anesthetics, 2.5% lidocaine and 2.5% prilocaine) cream
Number of subjects: 31

Group type: COMPARATOR
Intervention: Non-EMLA (placebo)
Number of subjects: 31
Study: 11158042

Group type: EXPERIMENTAL
Intervention: levormeloxifene 1.25 mg/day
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: levormeloxifene 5 mg/day
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: levormeloxifene 10 mg/day
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: levormeloxifene 20 mg/day
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: low dose HRT (1 mg 17 beta‐estradiol and 0.5 mg norethisterone acetate/day)
Number of subjects: 301

Group type: COMPARATOR
Intervention: placebo (500 mg calcium)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: levormeloxifene
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: low dose HRT
Number of subjects: 301

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 301
Study: 9764965

Group type: EXPERIMENTAL
Intervention: levobupivacaine
Number of subjects: 14

Group type: COMPARATOR
Intervention: rac-bupivacaine
Number of subjects: 14
Study: 7825466

Group type: EXPERIMENTAL
Intervention: Breast milk
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whey-based formula without bovine lactoferrin, iron or nucleotides
Number of subjects: 0

Group type: COMPARATOR
Intervention: Formula feeding (general)
Number of subjects: 0
Study: 3293762

Group type: EXPERIMENTAL
Intervention: HLA-matched single-donor platelet transfusions
Number of subjects: 78

Group type: COMPARATOR
Intervention: Mismatched single-donor platelet transfusions
Number of subjects: 78
Study: 29635632

Group type: EXPERIMENTAL
Intervention: Hydromorphone immediate-release tablets at a dose converted at a hydromorphone:morphine ratio of 1:5
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Hydromorphone immediate-release tablets at a dose converted at a hydromorphone:morphine ratio of 1:8
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 71
Study: 26893030

Group type: EXPERIMENTAL
Intervention: Exercise group (supine treadmill exercise within lower body negative pressure for 3-4 days/wk and flywheel resistive exercise for 2-3 days/wk)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study: 25511551

Group type: EXPERIMENTAL
Intervention: Daily intravaginal 0.50% prasterone for 2 weeks followed by twice weekly for 10 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23229772

Group type: EXPERIMENTAL
Intervention: Auditory model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Auditory + visual model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (visual metronome)
Number of subjects: 0
Study: 21524710

Group type: EXPERIMENTAL
Intervention: Banana consumption (one medium banana twice a day)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Banana-flavoured drink (one cup twice a day)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Water (one cup twice a day)
Number of subjects: 34
Study: 19505388

Group type: EXPERIMENTAL
Intervention: Pre-co-seasonal sublingual immunotherapy with modified allergen extract
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study: 16772806

Group type: EXPERIMENTAL
Intervention: Oxycodone/Paracetamol 5/325 mg and 10/650 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bromfenac 25 mg and 50 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 15531006

Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg once daily (level 1)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg once daily (level 1)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg once daily (level 2)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg once daily (level 2)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 12.5 mg added (level 3)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Combined treatments (Valsartan and Amlodipine)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Patients with sustained hypertension
Number of subjects: 164
Study: 11513283

Group type: EXPERIMENTAL
Intervention: Various measures for assessing acute pain in infants; specific interventions not detailed.
Number of subjects: 0
Study: 9279269

Group type: EXPERIMENTAL
Intervention: Specialist-led physical education classes (40 min per week)
Number of subjects: 955

Group type: EXPERIMENTAL
Intervention: Teacher-led physical education classes (33 min per week)
Number of subjects: 955

Group type: COMPARATOR
Intervention: Control classes (18 min per week)
Number of subjects: 955

Group type: EXPERIMENTAL
Intervention: Specialist-led condition for girls
Number of subjects: 955
Study: 8356997

Group type: EXPERIMENTAL
Intervention: nabumetone (1,000‐2,000 mg/day)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: diclofenac (100‐200 mg/day)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: naproxen (500‐1,500 mg/day)
Number of subjects: 1000
Study: 3064591

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 29091527

Group type: EXPERIMENTAL
Intervention: Class-Based (CB) Exercise
Number of subjects: 172

Group type: COMPARATOR
Intervention: Home-Based (HB) Exercise
Number of subjects: 172
Study: 28851317

Group type: EXPERIMENTAL
Intervention: NaturaLyte® acid concentrate (4 mEq/L acetate)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: GranuFlo® acid concentrate (8 mEq/L acetate)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Both NaturaLyte® and GranuFlo®
Number of subjects: 11
Study: 25498218

Group type: EXPERIMENTAL
Intervention: Immediate chemotherapy (four cycles of gemcitabine plus cisplatin, high-dose methotrexate, vinblastine, doxorubicin, and cisplatin [high-dose MVAC])
Number of subjects: 284

Group type: COMPARATOR
Intervention: Deferred chemotherapy (six cycles at relapse)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Immediate chemotherapy
Number of subjects: 284

Group type: COMPARATOR
Intervention: Deferred chemotherapy
Number of subjects: 284
Study: 23683266

Group type: EXPERIMENTAL
Intervention: 3.6 g/d of omega-3 fatty acid (O3A) ethyl esters
Number of subjects: 48
Study: 17038572

Group type: EXPERIMENTAL
Intervention: Exercise rehabilitation for 6 months
Number of subjects: 702

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 702
Study: 12839147

Group type: EXPERIMENTAL
Intervention: Telithromycin 800 mg once daily for 5 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Penicillin V 500 mg 3 times daily for 10 days
Number of subjects: 0
Study: 10435684

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Ampicillin-sulbactam (sultamicillin)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Cefaclor monohydrate
Number of subjects: 106
Study: 7848019

Group type: EXPERIMENTAL
Intervention: Postoperative prophylaxis for VTE (specifics not provided)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preoperative prophylaxis for VTE (specifics not provided)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Twice-daily, low-molecular-weight heparin
Number of subjects: 0
Study: 2248843

Group type: EXPERIMENTAL
Intervention: Combination of bupivacaine and lignocaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2% lignocaine with adrenaline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bupivacaine alone
Number of subjects: 0
Study: 7425697

Group type: EXPERIMENTAL
Intervention: High protein diet supplemented with milk whey protein
Number of subjects: 18
Study: 30422193

Group type: EXPERIMENTAL
Intervention: Pharmacist-led educational intervention
Number of subjects: 489

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Sedative-hypnotics (intervention)
Number of subjects: 489

Group type: COMPARATOR
Intervention: Sedative-hypnotics (control)
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Glyburide (intervention)
Number of subjects: 489

Group type: COMPARATOR
Intervention: Glyburide (control)
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drugs (intervention)
Number of subjects: 489

Group type: COMPARATOR
Intervention: Nonsteroidal anti-inflammatory drugs (control)
Number of subjects: 489
Study: 27375714

Group type: EXPERIMENTAL
Intervention: 1 mg/kg propofol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1 mg/kg ketamine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg propofol plus 0.5 mg/kg ketamine
Number of subjects: 60
Study: 26242117

Group type: EXPERIMENTAL
Intervention: Bushen Shuji Granule (BSG)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Celecoxib Capsule (Control)
Number of subjects: 62
Study: 23768121

Group type: EXPERIMENTAL
Intervention: Plyometric program
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Core stability program
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23
Study: 20667337

Group type: EXPERIMENTAL
Intervention: Papillary muscle repositioning (PMR)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Total chordal-sparing mitral valve replacement
Number of subjects: 50
Study: 18431218

Group type: EXPERIMENTAL
Intervention: Tobacco cessation intervention (Ask and Advise + fax referral to quitline)
Number of subjects: 240
Study: 15657341

Group type: EXPERIMENTAL
Intervention: Chemotherapy and radiation therapy (37.5 Gy in 16 fractions)
Number of subjects: 318
Study: 12558306

Group type: EXPERIMENTAL
Intervention: Midazolam via ECMO circuit
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous midazolam
Number of subjects: 20
Study: 10589645

Group type: EXPERIMENTAL
Intervention: Thermostat device (hypothermia warming mitt/seal and thermal exchange chamber for 60 min)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional treatment (warm blankets and/or radiant heat)
Number of subjects: 60
Study: 7847521

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1 gm daily intravenous)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Cefazolin (2 gm three times daily intravenous)
Number of subjects: 178
Study: 1819436

Group type: EXPERIMENTAL
Intervention: Combined yellow‐fever‐measles vaccine
Number of subjects: 453

Group type: COMPARATOR
Intervention: Yellow‐fever and measles separate administration
Number of subjects: 453
Study: 7199334

Group type: EXPERIMENTAL
Intervention: Midazolam maleate
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 30
Study: 31877392

Group type: EXPERIMENTAL
Intervention: Infant carrying (babywearing) for 1 hour daily for 3 months
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (reading)
Number of subjects: 33
Study: 30758327

Group type: EXPERIMENTAL
Intervention: Ketamine (subanesthetic dose)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 28466151

Group type: EXPERIMENTAL
Intervention: Multifaceted interventions including local quality improvement teams, educational outreach, audit, feedback, and reminders.
Number of subjects: 4183

Group type: COMPARATOR
Intervention: Conventional continuous medical education (CME) measures.
Number of subjects: 4183

Group type: EXPERIMENTAL
Intervention: Delay in antimicrobial therapy.
Number of subjects: 4183

Group type: EXPERIMENTAL
Intervention: Delay in source control.
Number of subjects: 4183
Study: 26503395

Group type: EXPERIMENTAL
Intervention: Supportive educational intervention for carers (4 components: initial telephone assessment, tailored resource folder, home visit, ongoing monthly support for 12 months)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 240
Study: 23813851

Group type: EXPERIMENTAL
Intervention: Nurse-coordinated prevention programme (four outpatient nurse clinic visits focusing on healthy lifestyles, biometric risk factors, and medication adherence)
Number of subjects: 754

Group type: EXPERIMENTAL
Intervention: Nurse-coordinated prevention programme
Number of subjects: 754

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 754
Study: 22118755

Group type: EXPERIMENTAL
Intervention: Longevinex administered for 3 months (Group A)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Longevinex administered between 3 and 6 months (Group B)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard treatment (Control)
Number of subjects: 34
Study: 19302901

Group type: EXPERIMENTAL
Intervention: Posaconazole 200 mg BID for 7 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Posaconazole 400 mg BID for 7 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ketoconazole 400 mg once daily for 7 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Midazolam (oral 2 mg and IV 0.4 mg) administered with either azole
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Adverse events reported with posaconazole alone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Adverse events reported with ketoconazole alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Adverse events reported with posaconazole + midazolam
Number of subjects: 12
Study: 17582178

Group type: EXPERIMENTAL
Intervention: Systemic steroids (Methyl prednisolone 0.5 mg/kg/day in two divided doses)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Nebulized steroids (Budecort 50 mcg/dose twice daily)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no steroids)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 51
Study: 15449752

Group type: EXPERIMENTAL
Intervention: 500 ml of 6% hydroxyethylstarch (HES)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 1000 ml of 6% hydroxyethylstarch (HES)
Number of subjects: 75

Group type: COMPARATOR
Intervention: No preload (Control)
Number of subjects: 75
Study: 11343734

Group type: EXPERIMENTAL
Intervention: Treatment by primary-care physician
Number of subjects: 988

Group type: EXPERIMENTAL
Intervention: Treatment by pain specialist
Number of subjects: 988

Group type: EXPERIMENTAL
Intervention: Overall experience of pain
Number of subjects: 988

Group type: EXPERIMENTAL
Intervention: Overall desire for additional treatment
Number of subjects: 988

Group type: EXPERIMENTAL
Intervention: Demographics
Number of subjects: 988
Study: 9518909

Group type: EXPERIMENTAL
Intervention: temazepam 10 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 11
Study: 7853442

Group type: EXPERIMENTAL
Intervention: Manioc Salt Solution (MSS)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Pap Salt Solution (PSS)
Number of subjects: 333

Group type: COMPARATOR
Intervention: World Health Organization/Oral Rehydration Solution (WHO/ORS)
Number of subjects: 333
Study: 2768761

Group type: EXPERIMENTAL
Intervention: Mixed meal
Number of subjects: 6

Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 6
Study: 189333

Group type: EXPERIMENTAL
Intervention: 30 mg ACTH 4-10 subcutaneously
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31821210

Group type: EXPERIMENTAL
Intervention: Care received in Rwanda (intervention group)
Number of subjects: 1413

Group type: EXPERIMENTAL
Intervention: Care sought in Rwanda (intervention group)
Number of subjects: 1413

Group type: COMPARATOR
Intervention: Care received in Sierra Leone (control group)
Number of subjects: 1413

Group type: COMPARATOR
Intervention: Care sought in Sierra Leone (control group)
Number of subjects: 1413

Group type: EXPERIMENTAL
Intervention: Predictors for receiving care (multivariate analysis)
Number of subjects: 1413

Group type: EXPERIMENTAL
Intervention: Predictors for not receiving care (multivariate analysis)
Number of subjects: 1413
Study: 31693803

Group type: EXPERIMENTAL
Intervention: Tetravalent dengue vaccine (TAK-003)
Number of subjects: 20071

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20071
Study: 28481726

Group type: EXPERIMENTAL
Intervention: RV3-BB vaccine (neonatal schedule)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: RV3-BB vaccine (infant schedule)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: RV3-BB vaccine (both schedules)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: RV3-BB vaccine
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 25954737

Group type: EXPERIMENTAL
Intervention: Azithromycin (30 mg/kg, three once-weekly doses)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study: 23460821

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 22082783

Group type: EXPERIMENTAL
Intervention: Carbetocin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 60
Study: 19114797

Group type: EXPERIMENTAL
Intervention: ICD shock
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: History of chronic obstructive pulmonary disease (COPD)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: History of congestive heart failure
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Documented ventricular tachycardia (VT) at the time of ICD implant
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: High levels of anxiety
Number of subjects: 168
Study: 17145460

Group type: EXPERIMENTAL
Intervention: Prophylactic bracing
Number of subjects: 83

Group type: COMPARATOR
Intervention: Prophylactic taping
Number of subjects: 83
Study: 12626849

Group type: EXPERIMENTAL
Intervention: Donepezil treatment
Number of subjects: 61
Study: 11739308

Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) at -15 mm Hg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) at -20 mm Hg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) at -10 mm Hg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) at -40 mm Hg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) at -30 mm Hg
Number of subjects: 10
Study: 8922489

Group type: EXPERIMENTAL
Intervention: Long-term bone marrow cultures in patients with essential thrombocythaemia and polycythaemia vera
Number of subjects: 11
Study: 1565758

Group type: EXPERIMENTAL
Intervention: sodium chloride (high sodium)
Number of subjects: 32

Group type: COMPARATOR
Intervention: placebo tablets (usual sodium)
Number of subjects: 32
Study: 3892749

Group type: EXPERIMENTAL
Intervention: Fluoride supplemented amalgam (Yata) containing 0.5% fluoride as stannous fluoride
Number of subjects: 196

Group type: COMPARATOR
Intervention: Non gamma 2 amalgam (Amalcap)
Number of subjects: 196
Study: 29882841

Group type: EXPERIMENTAL
Intervention: 2000 IU vitamin D₃ daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: 50,000 IU vitamin D₃ monthly
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Comparison of both groups
Number of subjects: 60
Study: 27640797

Group type: COMPARATOR
Intervention: Artificial cycle group
Number of subjects: 572

Group type: COMPARATOR
Intervention: Drospirenone and ethinylestradiol tablets group
Number of subjects: 572

Group type: COMPARATOR
Intervention: Sodium hyaluronate group
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Control group
Number of subjects: 572
Study: 25948432

Group type: EXPERIMENTAL
Intervention: Performance-based financing (PBF) scheme
Number of subjects: 29

Group type: COMPARATOR
Intervention: Traditional input-based funding (non-PBF)
Number of subjects: 29
Study: 22684569

Group type: EXPERIMENTAL
Intervention: Combined treatment with tyrosine, lecithin, L‐glutamine and 5‐HTP, n=41
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo, n=42
Number of subjects: 83
Study: 20170333

Group type: EXPERIMENTAL
Intervention: Fixed-dose budesonide/formoterol 160/4.5 microg x 2 inhalations (320/9 mug) twice daily
Number of subjects: 1225

Group type: COMPARATOR
Intervention: Fixed-dose fluticasone propionate/salmeterol 250/50 microg twice daily
Number of subjects: 1225

Group type: EXPERIMENTAL
Intervention: Adjustable-dose budesonide/formoterol (adjustable from 320/9 microg twice daily to 320/9 microg once daily or 640/18 microg twice daily)
Number of subjects: 1225
Study: 18693154

Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% and benzoyl peroxide 2.5% (adapalene/BPO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adapalene 0.1%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Benzoyl peroxide 2.5%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tazarotene 0.1% gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: BPO 10% gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gel vehicle
Number of subjects: 0
Study: 16036492

Group type: EXPERIMENTAL
Intervention: Blood pressure measurement protocols involving multiple measurements and standardized techniques
Number of subjects: 3688

Group type: EXPERIMENTAL
Intervention: Training of operators and auditing of blood pressure measurement
Number of subjects: 3688

Group type: EXPERIMENTAL
Intervention: Blood pressure recording protocols and elimination of digit preferences
Number of subjects: 3688